Hikma Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Hikma Pharmaceuticals has a total shareholder equity of $2.3B and total debt of $1.2B, which brings its debt-to-equity ratio to 53.2%. Its total assets and total liabilities are $4.8B and $2.5B respectively. Hikma Pharmaceuticals's EBIT is $712.0M making its interest coverage ratio 11. It has cash and short-term investments of $260.0M.
Key information
53.2%
Debt to equity ratio
US$1.22b
Debt
| Interest coverage ratio | 11x |
| Cash | US$260.00m |
| Equity | US$2.30b |
| Total liabilities | US$2.55b |
| Total assets | US$4.85b |
Recent financial health updates
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Financial Position Analysis
Short Term Liabilities: HIK's short term assets ($2.3B) exceed its short term liabilities ($1.4B).
Long Term Liabilities: HIK's short term assets ($2.3B) exceed its long term liabilities ($1.2B).
Debt to Equity History and Analysis
Debt Level: HIK's net debt to equity ratio (41.9%) is considered high.
Reducing Debt: HIK's debt to equity ratio has increased from 34.1% to 53.2% over the past 5 years.
Debt Coverage: HIK's debt is well covered by operating cash flow (47.8%).
Interest Coverage: HIK's interest payments on its debt are well covered by EBIT (11x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 09:42 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 37 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| Simon Mather | Barclays |
| Emily Field | Barclays |